Trends in CNS Dealmaking, Market

Diseases of the central nervous system (CNS) offer considerable opportunity to drug developers and marx`keters. A few CNS markets, such as multiple sclerosis, are already highly competitive, whereas others including potential blockbuster areas like Alzheimer’s disease offer a kind of therapeutic whitespace where few if any drugs are approved, and the medical need is dire. Regardless of the level of competition in a specific therapeutic area, there remains significant unmet medical need in virtually all CNS disease areas. Drug discovery and development have proven exceptionally difficult in this space, but better disease categorization and diagnosis – through the use of genetic markers or imaging technology, for example – may improve success for CNS drug developers.

The field has proven so challenging in the past that many larger companies exited CNS drug development. Companies that have remained active in CNS and others that are rejoining the fray argue that the space is poised for a breakout. Is CNS now where oncology was 10 years ago? Here we will review dealmaking in the CNS space, to determine what kinds of assets are being pursued by the biopharmaceutical industry, whether dealmaking has intensified over the past five years, and in what particular areas of CNS companies are focusing their deal dollars.

According to an analysis of US Food and Drug Administration (FDA) data, only 12 therapeutics were approved for CNS indications between 2012 and 2016, compared with 19 during the prior five-year period. Putting that figure in additional context: during 2012–16, the FDA approved 50 new oncology therapies, compared with 24 from 2007–11. Moreover, the CNS space (including pain and psychiatry) was the only major therapeutic area to see a decrease in approvals from the 2007–11 period to the 2012–16 period. Even relatively moribund and generic-dominated therapeutic areas like respiratory and cardiovascular diseases enjoyed an uptick in FDA approvals.

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42324

Report Contents

EXECUTIVE SUMMARY

DEAL SET OVERVIEW
Company formation (measured by Series A financings)
Initial public offerings
Alliances
Mergers and acquisitions

TRENDS IN CNS COMPANY FORMATION
Venture investment in CNS is increasing
Strategic investors piling in to Series As
Bibliography

TRENDS IN CNS COMPANY IPOS
CNS IPOs follow broad industry trends
Bibliography

TRENDS IN CNS COMPANY DEALMAKING
Fewer but more valuable CNS alliances
Characteristics of CNS therapeutics buyers and sellers
CNS therapeutics M&A analysis
Bibliography

APPENDIX
About the author
Scope
Inclusions and exclusions
Categorization and classification
Measuring investor return

TOC Continued……!

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42324

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: [email protected]

Phone: +1 (617) 398-1947